Treatment of severe cases of pandemic (H1N1) 2009 influenza: review of antivirals and adjuvant therapy.
Identifieur interne : 000064 ( 1968/Analysis ); précédent : 000063; suivant : 000065Treatment of severe cases of pandemic (H1N1) 2009 influenza: review of antivirals and adjuvant therapy.
Auteurs : Gonzalo M L. Bearman [États-Unis] ; Shivanjali Shankaran ; Kara ElamSource :
- Recent patents on anti-infective drug discovery [ 2212-4071 ] ; 2010.
Descripteurs français
- KwdFr :
- MESH :
- traitement médicamenteux : Grippe humaine.
- usage thérapeutique : Antiviraux.
- Flambées de maladies, Grippe humaine, Humains, Sous-type H1N1 du virus de la grippe A, Traitement médicamenteux adjuvant.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Antiviral Agents.
- drug effects : Influenza A Virus, H1N1 Subtype.
- drug therapy : Influenza, Human.
- methods : Chemotherapy, Adjuvant.
- prevention & control : Disease Outbreaks, Influenza, Human.
- Humans.
Abstract
Three worldwide influenza pandemics were reported in the 20th century: in 1918, 1957 and 1968. All three pandemics were caused by different sub-types of Influenza A viruses: H1N1, H2N2 and H3N2 respectively. In early March 2009, the first cases of influenza -like illness (ILI) were reported from Mexico. This strain was identified as influenza A/ H1N1 strain. Pandemic (H1N1) 2009 influenza most commonly causes a self-limited illness, however, significant morbidity and mortality were reported in the young, the obese and in pregnant women. The drugs of choice for treatment and prophylaxis of pandemic (H1N1) 2009 influenza are the neuraminidase inhibitors, Oseltamivir and Zanamivir. While a few cases of Oseltamivir-resistance are reported, these isolates still retained their susceptibility to the inhaled Neuraminidase inhibitor, Zanamivir. Pandemic (H1N1) 2009 influenza virus is routinely resistant to the adamantanes: Amantadine and Rimantadine. These agents should not be used for the treatment or prophylaxis of pandemic (H1N1) 2009 influenza. The FDA recently approved the emergency use of Peramivir, an intravenous neuraminidase inhibitor, for the treatment of patients with severe influenza. We discuss the use of available antivirals, as well as the effectiveness of adjunctive therapies with immunomodulatory and anti-inflammatory agents, such as immunoglobulins and statins, for the treatment and management of patients with severe H1N1 influenza. This review summarizes the recent patents for the use of antivirals in treatment of severe influenza.
DOI: 10.2174/157489110791233513
PubMed: 20334616
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000205
- to stream PubMed, to step Curation: 000205
- to stream PubMed, to step Checkpoint: 000171
- to stream Ncbi, to step Merge: 000507
- to stream Ncbi, to step Curation: 000507
- to stream Ncbi, to step Checkpoint: 000507
- to stream Main, to step Merge: 000E07
- to stream Main, to step Curation: 000E01
- to stream Main, to step Exploration: 000E01
- to stream 1968, to step Extraction: 000064
Links to Exploration step
pubmed:20334616Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Treatment of severe cases of pandemic (H1N1) 2009 influenza: review of antivirals and adjuvant therapy.</title><author><name sortKey="Bearman, Gonzalo M L" sort="Bearman, Gonzalo M L" uniqKey="Bearman G" first="Gonzalo M L" last="Bearman">Gonzalo M L. Bearman</name><affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Virginia Commonwealth University Medical Center, Richmond, VA, USA. gbearman@mcvh-vcu.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Virginia Commonwealth University Medical Center, Richmond, VA</wicri:regionArea><wicri:noRegion>VA</wicri:noRegion></affiliation></author><author><name sortKey="Shankaran, Shivanjali" sort="Shankaran, Shivanjali" uniqKey="Shankaran S" first="Shivanjali" last="Shankaran">Shivanjali Shankaran</name></author><author><name sortKey="Elam, Kara" sort="Elam, Kara" uniqKey="Elam K" first="Kara" last="Elam">Kara Elam</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20334616</idno><idno type="pmid">20334616</idno><idno type="doi">10.2174/157489110791233513</idno><idno type="wicri:Area/PubMed/Corpus">000205</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000205</idno><idno type="wicri:Area/PubMed/Curation">000205</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000205</idno><idno type="wicri:Area/PubMed/Checkpoint">000171</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000171</idno><idno type="wicri:Area/Ncbi/Merge">000507</idno><idno type="wicri:Area/Ncbi/Curation">000507</idno><idno type="wicri:Area/Ncbi/Checkpoint">000507</idno><idno type="wicri:Area/Main/Merge">000E07</idno><idno type="wicri:Area/Main/Curation">000E01</idno><idno type="wicri:Area/Main/Exploration">000E01</idno><idno type="wicri:Area/1968/Extraction">000064</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Treatment of severe cases of pandemic (H1N1) 2009 influenza: review of antivirals and adjuvant therapy.</title><author><name sortKey="Bearman, Gonzalo M L" sort="Bearman, Gonzalo M L" uniqKey="Bearman G" first="Gonzalo M L" last="Bearman">Gonzalo M L. Bearman</name><affiliation wicri:level="1"><nlm:affiliation>Division of Infectious Diseases, Virginia Commonwealth University Medical Center, Richmond, VA, USA. gbearman@mcvh-vcu.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Virginia Commonwealth University Medical Center, Richmond, VA</wicri:regionArea><wicri:noRegion>VA</wicri:noRegion></affiliation></author><author><name sortKey="Shankaran, Shivanjali" sort="Shankaran, Shivanjali" uniqKey="Shankaran S" first="Shivanjali" last="Shankaran">Shivanjali Shankaran</name></author><author><name sortKey="Elam, Kara" sort="Elam, Kara" uniqKey="Elam K" first="Kara" last="Elam">Kara Elam</name></author></analytic><series><title level="j">Recent patents on anti-infective drug discovery</title><idno type="eISSN">2212-4071</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (therapeutic use)</term><term>Chemotherapy, Adjuvant (methods)</term><term>Disease Outbreaks (prevention & control)</term><term>Humans</term><term>Influenza A Virus, H1N1 Subtype (drug effects)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (prevention & control)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux (usage thérapeutique)</term><term>Flambées de maladies ()</term><term>Grippe humaine ()</term><term>Grippe humaine (traitement médicamenteux)</term><term>Humains</term><term>Sous-type H1N1 du virus de la grippe A ()</term><term>Traitement médicamenteux adjuvant ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Influenza A Virus, H1N1 Subtype</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemotherapy, Adjuvant</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Flambées de maladies</term><term>Grippe humaine</term><term>Humains</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Traitement médicamenteux adjuvant</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Three worldwide influenza pandemics were reported in the 20th century: in 1918, 1957 and 1968. All three pandemics were caused by different sub-types of Influenza A viruses: H1N1, H2N2 and H3N2 respectively. In early March 2009, the first cases of influenza -like illness (ILI) were reported from Mexico. This strain was identified as influenza A/ H1N1 strain. Pandemic (H1N1) 2009 influenza most commonly causes a self-limited illness, however, significant morbidity and mortality were reported in the young, the obese and in pregnant women. The drugs of choice for treatment and prophylaxis of pandemic (H1N1) 2009 influenza are the neuraminidase inhibitors, Oseltamivir and Zanamivir. While a few cases of Oseltamivir-resistance are reported, these isolates still retained their susceptibility to the inhaled Neuraminidase inhibitor, Zanamivir. Pandemic (H1N1) 2009 influenza virus is routinely resistant to the adamantanes: Amantadine and Rimantadine. These agents should not be used for the treatment or prophylaxis of pandemic (H1N1) 2009 influenza. The FDA recently approved the emergency use of Peramivir, an intravenous neuraminidase inhibitor, for the treatment of patients with severe influenza. We discuss the use of available antivirals, as well as the effectiveness of adjunctive therapies with immunomodulatory and anti-inflammatory agents, such as immunoglobulins and statins, for the treatment and management of patients with severe H1N1 influenza. This review summarizes the recent patents for the use of antivirals in treatment of severe influenza.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country></list><tree><noCountry><name sortKey="Elam, Kara" sort="Elam, Kara" uniqKey="Elam K" first="Kara" last="Elam">Kara Elam</name><name sortKey="Shankaran, Shivanjali" sort="Shankaran, Shivanjali" uniqKey="Shankaran S" first="Shivanjali" last="Shankaran">Shivanjali Shankaran</name></noCountry><country name="États-Unis"><noRegion><name sortKey="Bearman, Gonzalo M L" sort="Bearman, Gonzalo M L" uniqKey="Bearman G" first="Gonzalo M L" last="Bearman">Gonzalo M L. Bearman</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/1968/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000064 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/1968/Analysis/biblio.hfd -nk 000064 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= 1968
|étape= Analysis
|type= RBID
|clé= pubmed:20334616
|texte= Treatment of severe cases of pandemic (H1N1) 2009 influenza: review of antivirals and adjuvant therapy.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/1968/Analysis/RBID.i -Sk "pubmed:20334616" \
| HfdSelect -Kh $EXPLOR_AREA/Data/1968/Analysis/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |